Myomar Molecular is the latest company to join Emergence, Atlantic Canada’s bioscience business incubator which is dedicated to assisting start-ups and growth-stage companies in the commercialization of bioscience-based technologies and services. Myomar Molecular is developing a diagnostic tool to identify early stages of muscle atrophy. This technology will be used by physiotherapists and medical doctors to access therapy approaches, reduce hospitalization time, and analyze recovery progress.
“We are pleased to have Myomar Molecular join Emergence,” said Jason Cleaversmith, Director of Incubation, PEI BioAlliance. “We look forward to supporting Myomar’s growth ambitions and working with them on the clinical development of their product.”
Myomar’s goal is to provide a measurable way to identify early markers of muscle loss, something that impacts both quality of life and life expectancy. In doing so, they aim to create solutions to monitor and better treat muscle loss in order facilitate a faster recovery process and empower healthy aging. Their vision is to translate science and laboratory discovery for the benefit of society and to improve and innovate health care.
“As we initiate our regulatory journey and commercialization phase, we are looking forward to working with Emergence to speed up and facilitate this process,” said Rafaela Andrade, CEO and Co-Founder, Myomar Molecular. “We have nearly 900 people signed up for our Beta tests and we are working hard to put the technology in the market.”
Myomar was recently selected as one of 12 start-ups in the second cohort of Invest Nova Scotia’s 2023-2024 Accelerate Program, as well as one four companies to receive investment at SAAS North 2023 (Firehood Angel Camp Program), which connected women founders with angel investors. Myomar was also recently featured on Life Sciences Nova Scotia’s New Wave podcast and in Atlantic Business Magazine.
Emergence provides companies with business incubation services including the Critical Path program, one-on-one and team mentorship, business strategy and advisory services, as well as access to the Emergence Performance Network. Emergence Advisor Chris Cowper-Smith is located in Nova Scotia and specializes in medical devices, supporting companies such as Myomar Molecular. Emergence also works closely with Life Sciences Nova Scotia to identify high impact companies that are a good fit with the Emergence Incubator.